-
[show abstract]
[hide abstract]
ABSTRACT: IntroductionAdvanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis. No reports have been
published concerning useful drugs for salvage chemotherapy for this type of cancer. We performed salvage therapy with gemcitabine
in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in
stabilizing recurrent lesions and controlling carcinomatous peritonitis.
Case reportA 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary. She had recurrent tumors after primary cytoreductive
surgery, which were unresectable and also resistant to paclitaxel, carboplatin, irinotecan, and oral etoposide. After three
courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic
metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and
splenic metastatic lesions was classified as 5-month stable disease. The toxicity of this drug was in the acceptable range.
ConclusionGemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary. It is necessary to consider the
use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.
Archives of Gynecology and Obstetrics 04/2012; 278(6):565-568. · 1.28 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: It has been suggested that expression of TGFß1 and its receptors [TGFß receptor type I (TßRI) and TGFß receptor type II (TßRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFß1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFß1, TßRI, and TßRII mRNA was assessed by the RNase protection assay. It was found that TGFß1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGFß1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. TßRI mRNA expression was not associated with any clinicopathological factors. Expression of TßRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGFß1, TßRI, and TßRII, expression of TGFß1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGFß1 mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGFß1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer.
Oncology Reports 01/2011; 25(4):1131-8. · 1.84 Impact Factor
-
Archives of Gynecology 01/2009; · 0.91 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis. No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer. We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis.
A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary. She had recurrent tumors after primary cytoreductive surgery, which were unresectable and also resistant to paclitaxel, carboplatin, irinotecan, and oral etoposide. After three courses of fourth-line chemotherapy with gemcitabine for the treatment of carcinomatous peritonitis and hepatic and splenic metastatic lesions, serum CA-125 and the severity of ascites showed marked decreases, and its efficacy for the hepatic and splenic metastatic lesions was classified as 5-month stable disease. The toxicity of this drug was in the acceptable range.
Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary. It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.
Archives of Gynecology 07/2007; 278(6):565-8. · 0.91 Impact Factor
-
Acta Obstetricia Et Gynecologica Scandinavica 09/2005; 84(8):820-2. · 1.77 Impact Factor
-
European Journal of Obstetrics & Gynecology and Reproductive Biology 12/2004; 117(1):112-4. · 1.97 Impact Factor
-
European Journal of Obstetrics & Gynecology and Reproductive Biology 11/2004; 116(2):242-3. · 1.97 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: INTRODUCTION: There is no established treatment for vaginal cancer at present. Cases of squamous cell carcinoma reported in the literature have been treated primarily by radiotherapy. We report a case of pT4 vaginal adenocarcinoma, in which radical surgery seemed to prolong the disease-free period.
Archives of Gynecology and Obstetrics 09/2003; 268(3):214-6. · 1.28 Impact Factor
